China-based macromolecule-focused Contract Development and Manufacturing Organization (CDMO) Intellective Biologics (Suzhou) Co., Ltd has reportedly raised over RMB500 million (USD74.1 million) in a Series C financing round. The round was co-led by Tsing Song Capital and Gaorong Capital, with participation from Fuho Capital, CNCB Investment, Founder Securities, and Win Harbor Capital. The proceeds will be used to enhance the company’s commercial manufacturing capacity, technology platform, global operation layout, and talent team.
Company Background
Founded in 2018, Intellective Biologics offers a comprehensive range of services covering monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), multispecific antibodies, fusion proteins, vaccines, antibody drug conjugates (ADCs), and more. The company boasts a GMP production platform, ADC platform, multiple culture platforms, autonomous cell construction platform, druggability analysis platform, virus safety detection platform, and preparation development platform.-Fineline Info & Tech
